EA201790417A2 - Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов - Google Patents
Конденсированные гетероциклические соединения в качестве модуляторов ионных каналовInfo
- Publication number
- EA201790417A2 EA201790417A2 EA201790417A EA201790417A EA201790417A2 EA 201790417 A2 EA201790417 A2 EA 201790417A2 EA 201790417 A EA201790417 A EA 201790417A EA 201790417 A EA201790417 A EA 201790417A EA 201790417 A2 EA201790417 A2 EA 201790417A2
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- modulators
- heterocyclic compounds
- ion channels
- condensed heterocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Photoreceptors In Electrophotography (AREA)
- Television Systems (AREA)
Abstract
Настоящее изобретение относится к соединениям, представляющим собой ингибиторы натриевого канала, и к их применению в лечении различных болезненных состояний, включая сердечно-сосудистые заболевания и диабет. Согласно конкретным вариантам реализации структура соединений согласно настоящему изобретению представлена формулой Iгде Z, Z, Z, Z, X, Y, R, Rи Rтакие, как описано в описании изобретения, а также к способам получения и применения соединений согласно настоящему изобретению и к фармацевтическим композициям, содержащим указанные соединения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161503980P | 2011-07-01 | 2011-07-01 | |
US201161582160P | 2011-12-30 | 2011-12-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201790417A2 true EA201790417A2 (ru) | 2017-07-31 |
EA201790417A3 EA201790417A3 (ru) | 2017-11-30 |
Family
ID=46513866
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201391639A EA027356B1 (ru) | 2011-07-01 | 2012-06-29 | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
EA201790417A EA201790417A3 (ru) | 2011-07-01 | 2012-06-29 | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201391639A EA027356B1 (ru) | 2011-07-01 | 2012-06-29 | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
Country Status (37)
Country | Link |
---|---|
US (5) | US8586732B2 (ru) |
EP (6) | EP3101013B1 (ru) |
JP (2) | JP5889407B2 (ru) |
KR (2) | KR101608927B1 (ru) |
CN (2) | CN103857659B (ru) |
AP (1) | AP2013007300A0 (ru) |
AR (1) | AR086828A1 (ru) |
AU (1) | AU2012279236B2 (ru) |
BR (1) | BR112013032361A2 (ru) |
CA (1) | CA2838223A1 (ru) |
CL (1) | CL2013003598A1 (ru) |
CO (1) | CO6821960A2 (ru) |
CR (1) | CR20130658A (ru) |
CY (1) | CY1117915T1 (ru) |
DK (1) | DK2726466T3 (ru) |
EA (2) | EA027356B1 (ru) |
EC (1) | ECSP13013083A (ru) |
ES (6) | ES2842433T3 (ru) |
HK (6) | HK1196602A1 (ru) |
HR (1) | HRP20160952T1 (ru) |
HU (1) | HUE029398T2 (ru) |
IL (2) | IL230022B (ru) |
MD (1) | MD4371C1 (ru) |
ME (1) | ME02546B (ru) |
MX (1) | MX336810B (ru) |
NZ (2) | NZ618691A (ru) |
PE (1) | PE20140690A1 (ru) |
PL (1) | PL2726466T3 (ru) |
PT (1) | PT2726466T (ru) |
RS (1) | RS55024B1 (ru) |
SI (1) | SI2726466T1 (ru) |
SM (1) | SMT201600271B (ru) |
TW (4) | TWI478908B (ru) |
UA (1) | UA115529C2 (ru) |
UY (1) | UY34171A (ru) |
WO (1) | WO2013006485A1 (ru) |
ZA (1) | ZA201308981B (ru) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
CN102725290B (zh) | 2009-07-27 | 2016-03-09 | 吉利德科学股份有限公司 | 作为离子通道调节剂的稠合杂环化合物 |
PT2588197E (pt) | 2010-07-02 | 2015-02-09 | Gilead Sciences Inc | Compostos heterocíclicos fundidos como moduladores do canal de iões |
CN105693645B (zh) | 2011-05-10 | 2018-10-09 | 吉利德科学公司 | 作为离子通道调节剂的稠合杂环化合物 |
TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (ru) | 2011-07-01 | 2018-04-28 | ||
WO2013137922A2 (en) | 2011-08-05 | 2013-09-19 | Illumina, Inc. | Functionalization and purification of molecules by reversible group exchange |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
WO2013112932A1 (en) * | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US20140329755A1 (en) * | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
SG11201600119PA (en) * | 2013-08-01 | 2016-02-26 | Gilead Sciences Inc | Compound and methods for treating long qt syndrome |
EP3027189A1 (en) | 2013-08-01 | 2016-06-08 | Gilead Sciences, Inc. | Method of treating hypertrophic cardiomyopathy |
SG11201601367QA (en) * | 2013-09-10 | 2016-03-30 | Chromocell Corp | Sodium channel modulators for the treatment of pain and diabetes |
EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
EP3083608B1 (en) * | 2013-12-19 | 2018-07-18 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
CN104844535A (zh) | 2014-02-13 | 2015-08-19 | 吉利德科学公司 | 用于制备稠合杂环离子通道调节剂的方法 |
TW201613908A (en) | 2014-02-13 | 2016-04-16 | Gilead Sciences Inc | Solid forms of an ion channel modulator |
WO2015153153A1 (en) * | 2014-04-02 | 2015-10-08 | Gilead Sciences, Inc. | Methods of treating patients having implantable cardiac devices |
KR20170049605A (ko) | 2014-09-24 | 2017-05-10 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환의 치료 방법 |
TWI724770B (zh) | 2014-12-23 | 2021-04-11 | 美商基利科學股份有限公司 | 製備5-(4-環丙基-1h-咪唑-1-基)-n-(6-(4-異丙基-4h-1,2,4-三唑-3-基)吡啶-2-基)-2-氟-4-甲基苯甲醯胺之方法 |
MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
US20170007617A1 (en) * | 2015-07-09 | 2017-01-12 | Gilead Sciences Drive | Intravenous formulations of a late sodium current inhibitor |
WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
CN115028617A (zh) * | 2016-05-24 | 2022-09-09 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
US11091483B2 (en) | 2016-08-12 | 2021-08-17 | Madera Therapeutics, LLC | Protein kinase regulators |
WO2018048977A1 (en) * | 2016-09-08 | 2018-03-15 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxazepin compounds |
AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
JP7208137B2 (ja) | 2016-12-09 | 2023-01-18 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物および方法 |
US20200085838A1 (en) * | 2017-05-16 | 2020-03-19 | Praxis Precision Medicines, Inc. | Methods of treating epilepsy and neurodevelopmental disorders |
PE20200729A1 (es) | 2017-05-17 | 2020-07-23 | Denali Therapeutics Inc | Inhibidores de quinasa y usos de los mismos |
WO2019055877A1 (en) | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
WO2019173761A1 (en) | 2018-03-09 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
SG11202012767UA (en) | 2018-06-29 | 2021-01-28 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
EP3870173A4 (en) | 2018-10-24 | 2022-06-22 | Vanderbilt University | WDR5 MODULATORS AND INHIBITORS |
KR102172595B1 (ko) * | 2018-12-19 | 2020-11-02 | 인하대학교 산학협력단 | 벤조옥사제핀 유도체 화합물을 포함하는 비만 예방 또는 치료용 약학 조성물 |
CN109879830A (zh) * | 2019-03-27 | 2019-06-14 | 安徽师范大学 | 一种含环外双键的氧氮杂环庚烷衍生物及其制备方法 |
WO2020247679A1 (en) * | 2019-06-04 | 2020-12-10 | Vanderbilt University | Wdr5 inhibitors and modulators |
US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
MX2023009685A (es) | 2021-02-19 | 2023-10-30 | Sudo Biosciences Ltd | Inhibidores de tyk2 y sus usos. |
TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型 |
WO2023143389A1 (zh) * | 2022-01-29 | 2023-08-03 | 江苏恒瑞医药股份有限公司 | 稠杂环类化合物、其制备方法及其在医药上的应用 |
JPWO2023204308A1 (ru) * | 2022-04-22 | 2023-10-26 |
Family Cites Families (225)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2867618A (en) | 1957-02-14 | 1959-01-06 | Dow Chemical Co | 3, 4-dihydro-2h-1, 3-benzoxazine |
US2826575A (en) | 1957-05-06 | 1958-03-11 | Dow Chemical Co | 3, 3'-alkylenebis |
NL128591C (ru) | 1965-07-02 | |||
US3441649A (en) | 1966-08-18 | 1969-04-29 | Univ Minnesota | Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate |
US3594372A (en) | 1968-08-13 | 1971-07-20 | American Home Prod | Pyrimido(4,5-e)(1,4)oxazepin-5-ones and derivatives thereof |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4062881A (en) | 1974-07-26 | 1977-12-13 | Cincinnati Milacron Chemicals, Inc. | Sulfide containing tin stabilizers |
US4230705A (en) | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
US4244953A (en) | 1979-10-24 | 1981-01-13 | American Cyanamid Company | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines |
JPS5675428A (en) | 1979-11-21 | 1981-06-22 | Ayanori Takabe | Hypoglycemic agent containing procainamide hydrochloride |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4812565A (en) * | 1982-09-30 | 1989-03-14 | A. H. Robins Company, Incorporated | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
DE3382028D1 (de) * | 1982-09-30 | 1991-01-10 | Robins Co Inc A H | Kondensierte aromatische oxazepinone und sulphuranaloge, ihrer herstellung und verwendung als histamin-antagonist. |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4654343A (en) | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
JPH061779B2 (ja) | 1987-07-31 | 1994-01-05 | 田中電子工業株式会社 | 半導体装置の製造方法 |
RO96410B1 (ro) * | 1987-02-16 | 1989-03-02 | Institutul Politehnic | Derivati de 1,4-benzoxazepinona si procedeu pentru prepararea lor |
US4746655A (en) | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
DE4010488A1 (de) | 1990-03-31 | 1991-10-02 | Hoechst Ag | Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten |
CA2044564A1 (en) | 1990-06-28 | 1991-12-29 | Quirico Branca | Amino acid derivatives |
CN1060467A (zh) | 1990-09-25 | 1992-04-22 | 武田药品工业株式会社 | 1,3-苯并嗪衍生物、其生产方法和用途 |
JPH04209692A (ja) | 1990-12-03 | 1992-07-31 | Asahi Glass Co Ltd | フォトクロミック材料 |
DE69209576D1 (de) | 1991-05-10 | 1996-05-09 | Takeda Chemical Industries Ltd | Pyridinderivate, deren Herstellung und Anwendung |
US5939412A (en) * | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
DE69232854T2 (de) * | 1991-06-28 | 2003-09-04 | Smithkline Beecham Corp | Bizyklische fibrinogenantagonisten |
US5250679A (en) * | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
US5674863A (en) * | 1991-10-18 | 1997-10-07 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
JPH061779A (ja) | 1992-02-06 | 1994-01-11 | Wakamoto Pharmaceut Co Ltd | ベンズオキサジノン誘導体 |
JPH06107647A (ja) | 1992-08-12 | 1994-04-19 | Takeda Chem Ind Ltd | 1,3−ベンゾオキサジン誘導体の製造法 |
US6011150A (en) | 1992-11-13 | 2000-01-04 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
US5442055A (en) | 1992-11-13 | 1995-08-15 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
GB9225860D0 (en) | 1992-12-11 | 1993-02-03 | Smithkline Beecham Plc | Novel treatment |
GB9226302D0 (en) | 1992-12-17 | 1993-02-10 | Smithkline Beecham Plc | Pharmaceuticals |
US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
DE19526173A1 (de) | 1995-07-18 | 1997-01-30 | Hoechst Ag | Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung |
JPH09157262A (ja) | 1995-12-08 | 1997-06-17 | Tanabe Seiyaku Co Ltd | アゼチジノン誘導体及びその合成中間体の製法 |
US5773186A (en) | 1996-02-19 | 1998-06-30 | Fuji Photo Film Co., Ltd. | Heat-sensitive recording material |
GB9619492D0 (en) | 1996-09-18 | 1996-10-30 | Smithkline Beecham Plc | Novel treatment |
WO1998047885A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
AU7548298A (en) | 1997-05-30 | 1998-12-30 | Meiji Seika Kaisha Ltd. | Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same |
JP3964053B2 (ja) | 1997-07-10 | 2007-08-22 | 三井化学株式会社 | 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法 |
CN1131887C (zh) | 1997-09-08 | 2003-12-24 | 尤尼利弗公司 | 促进酶活性的方法 |
CN1110498C (zh) | 1998-01-21 | 2003-06-04 | 默克·夏普-道姆公司 | 作为gaba受体的配体的三唑并-哒嗪衍生物 |
US6455522B1 (en) * | 1998-02-11 | 2002-09-24 | Bristol-Myers Squibb Pharma Company | Cyclic sulfonamide derivatives as metalloproteinase inhibitors |
CN1293665A (zh) | 1998-02-18 | 2001-05-02 | 神经研究公司 | 新化合物及其用作阳性ampa受体调节剂 |
US6479506B1 (en) | 1998-06-16 | 2002-11-12 | Merck Sharp & Dohme Ltd. | Triazolo-pyridine derivatives as ligands for GABA receptors |
EP1123297A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
KR20020005662A (ko) | 1999-04-09 | 2002-01-17 | 기따자또 이찌로 | 질소함유 복소환화합물 및 벤즈아미드화합물 및 그 것을함유해서 되는 의약 |
AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
US6121916A (en) | 1999-07-16 | 2000-09-19 | Eaton-Vorad Technologies, L.L.C. | Method and apparatus for recognizing stationary objects with a moving side-looking radar |
TR200201062T2 (tr) | 1999-08-27 | 2003-02-21 | The Procter & Gamble Company | Formülasyon bileşenlerinin denetimli kullanılabilirliği ve bundan yararlanılan bileşimler. |
MXPA02002123A (es) | 1999-08-27 | 2002-10-17 | Procter & Gamble | Metodos de lavanderia que conservan el color, que emplean componentes de formulacion cationicos. |
WO2001016110A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Bleach boosting components, compositions and laundry methods |
EP1206516A1 (en) | 1999-08-27 | 2002-05-22 | The Procter & Gamble Company | Stability enhancing formulation components, compositions and laundry methods employing same |
WO2001016275A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Fast-acting formulation components, compositions and laundry methods employing same |
MXPA02002126A (es) | 1999-08-27 | 2002-09-18 | Procter & Gamble | Metodos de lavanderia que conservan el color, que emplean componentes de formulacion zwitterionicos. |
EP1206519B1 (en) | 1999-08-27 | 2005-11-30 | The Procter & Gamble Company | Stable formulation components, compositions and laundry methods employing same |
IL135092A0 (en) | 2000-03-15 | 2001-05-20 | Kidron Agrochem Ltd | A composition for the control of pests |
AU5652001A (en) | 2000-05-15 | 2001-11-26 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
RU2272030C2 (ru) | 2000-08-01 | 2006-03-20 | Оно Фармасьютикал Ко., Лтд. | Производные 3,4-дигидроизохинолина и фармацевтический агент, включающий его в качестве активного ингредиента |
US20020072518A1 (en) | 2000-08-29 | 2002-06-13 | Khanna Ish Kumar | Bicyclic alphavbeta3 antagonists |
JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
EP1354602B1 (en) | 2000-12-26 | 2006-10-04 | Sankyo Company, Limited | Medicinal compositions containing diuretic and insulin resistance-improving agent |
HUP0303415A2 (hu) | 2001-03-09 | 2004-01-28 | Pfizer Products Inc. | Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények |
US6998408B2 (en) | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
JP2005089298A (ja) | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
ATE374183T1 (de) | 2001-11-13 | 2007-10-15 | Schering Corp | Nk1-antagonisten |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
JP2003277384A (ja) | 2002-03-26 | 2003-10-02 | Kyorin Pharmaceut Co Ltd | 縮合ニ環式ピリジン誘導体 |
JP2003321461A (ja) | 2002-04-25 | 2003-11-11 | Kyorin Pharmaceut Co Ltd | 縮合ビフェニル誘導体 |
US20040152696A1 (en) * | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
MXPA05001785A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de cromona como inhibidores de las metaloproteinasas de matriz. |
BR0313724A (pt) | 2002-08-13 | 2005-06-28 | Warner Lambert Co | Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz |
DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US20040242572A1 (en) | 2002-08-24 | 2004-12-02 | Boehringer Ingelheim International Gmbh | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture |
US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
AU2003262073A1 (en) | 2002-09-20 | 2004-04-08 | Tsumura And Co. | Antitussives |
US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
AU2003294235A1 (en) | 2002-10-22 | 2004-05-13 | The Trustees Of The University Of Pennsylvania | Fragments and activity of rel protein in m. tuberculosis adn other uses thereof |
CN100430386C (zh) | 2002-11-07 | 2008-11-05 | 默克公司 | 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病 |
ES2278213T3 (es) | 2002-11-07 | 2007-08-01 | MERCK & CO., INC. | Derivados de fenilamina como inhibidores de la dipeptidilpeptidasa en el tratamiento o la prevencion de la diabetes. |
NZ540468A (en) | 2003-01-13 | 2008-03-28 | Univ California | Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator |
AR044503A1 (es) | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
DE10317526A1 (de) | 2003-04-16 | 2004-11-04 | Degussa Ag | Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen |
EP1622916A4 (en) | 2003-04-17 | 2008-11-05 | Merck & Co Inc | Heterocyclic CYCLOPENTYLTETRAHYDROISOCHINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY |
EP1631546A1 (en) | 2003-04-25 | 2006-03-08 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
WO2004101509A2 (en) | 2003-05-06 | 2004-11-25 | Case Western Reserve University | Functionalized benzoxazines, polymers and copolymers thereof |
WO2005002520A2 (en) | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
MXPA06000796A (es) | 2003-07-21 | 2006-04-07 | Solvay Pharm Gmbh | Uso de los compuestos 3,7-diazabiciclo [3,3,1]nonano para el tratamiento y/o profilaxis de eventos antiarritmicos en pacientes humanos varones. |
MXPA06001494A (es) | 2003-08-05 | 2007-05-11 | Vertex Pharma | Compuestos de piramidina condensados como inhibidores de canales ionicos gatillados por tension. |
US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
AU2004305318A1 (en) | 2003-12-18 | 2005-07-07 | Pfizer Products Inc. | Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors |
ZA200607637B (en) | 2004-03-05 | 2008-05-28 | Nissan Chemical Ind Ltd | Isoxazoline-substituted benzamide compound and noxious organism control agent |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
WO2006002470A1 (en) | 2004-06-30 | 2006-01-12 | Monash University | Chiral ligands for asymmetric catalysis |
JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
US7572783B2 (en) * | 2004-08-13 | 2009-08-11 | Amgen Inc. | Substituted benzofused heterocycles |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
CN101005877A (zh) | 2004-08-23 | 2007-07-25 | 默克公司 | 作为用于治疗或预防糖尿病的二肽基肽酶-ⅳ抑制剂的稠合三唑衍生物 |
ATE518852T1 (de) | 2004-09-13 | 2011-08-15 | Merck Sharp & Dohme | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten |
AR050948A1 (es) | 2004-09-24 | 2006-12-06 | Hoffmann La Roche | Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer. |
WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
JP2006203875A (ja) | 2004-12-24 | 2006-08-03 | Matsushita Electric Ind Co Ltd | 受信装置 |
WO2006091897A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
US20080176830A1 (en) * | 2005-04-14 | 2008-07-24 | Adams Nicholas D | Compounds, Compositions, and Methods |
AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
JP5794721B2 (ja) | 2005-05-17 | 2015-10-14 | サーコード バイオサイエンス インコーポレイテッド | 眼障害の治療のための組成物および方法 |
TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7572808B2 (en) | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
US7495111B2 (en) | 2005-06-17 | 2009-02-24 | Wyeth | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists |
WO2007004028A2 (en) | 2005-06-30 | 2007-01-11 | Ranbaxy Laboratories Limited | Processes for the preparation of penems and its intermediate |
EP1932549B1 (en) | 2005-08-26 | 2016-12-28 | AMNOS Co., Ltd. | Dried amnion and method for drying treatment of amnion |
WO2007038138A2 (en) | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
EP1940850A2 (en) | 2005-09-23 | 2008-07-09 | Schering Corporation | Fused tetracyclic mglur1 antagonists as therapeutic agents |
WO2007047604A2 (en) | 2005-10-18 | 2007-04-26 | Elixir Pharmaceuticals, Inc. | Sirt1 inhibition |
TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
EP1954268B1 (en) | 2005-11-18 | 2012-09-26 | Merck Sharp & Dohme Corp. | Spirolactam bicyclic cgrp receptor antagonists |
AU2006316627A1 (en) | 2005-11-18 | 2007-05-31 | Merck Sharp & Dohme Corp. | Spirolactam aryl CGRP receptor antagonists |
TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
US20070142376A1 (en) | 2005-12-16 | 2007-06-21 | Alcon, Inc. | Control of intraocular pressure using alk5 modulation agents |
US8013073B2 (en) | 2005-12-30 | 2011-09-06 | Chevron Oronite Company Llc | Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds |
JP2009531390A (ja) | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
WO2007132841A1 (ja) * | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
CA2654842A1 (en) | 2006-06-12 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines useful as modulators of ion channels |
EP2035372A1 (en) | 2006-06-29 | 2009-03-18 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
US20080011523A1 (en) | 2006-06-29 | 2008-01-17 | Packard Thomas G | Rotor energy augmented vehicle |
JP5642963B2 (ja) | 2006-06-30 | 2014-12-17 | スネシス ファーマシューティカルズ,インコーポレイティド | ピリジノニルpdk1阻害剤 |
WO2008007661A1 (fr) * | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique tricycique et son utilisation |
AU2007272009A1 (en) | 2006-07-12 | 2008-01-17 | Syngenta Limited | Triazolopyridine derivatives as herbicides |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
ES2397284T3 (es) | 2006-08-22 | 2013-03-06 | Ranbaxy Laboratories Limited | Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos |
CA2665214A1 (en) | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
WO2008051547A1 (en) | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
US8399452B2 (en) | 2006-10-28 | 2013-03-19 | Methylgene Inc. | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors |
US20100099676A1 (en) | 2006-11-02 | 2010-04-22 | Shionogi & Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
US20080153840A1 (en) | 2006-12-21 | 2008-06-26 | Luiz Belardinelli | Reduction of cardiovascular symptoms |
US8076350B2 (en) | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
WO2008094909A2 (en) | 2007-01-29 | 2008-08-07 | Xenon Pharmaceuticals Inc. | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
WO2008106077A1 (en) * | 2007-02-28 | 2008-09-04 | Merck & Co., Inc. | Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers |
WO2008108445A1 (ja) | 2007-03-07 | 2008-09-12 | Takeda Pharmaceutical Company Limited | ベンゾオキサゼピン誘導体およびその用途 |
GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
CN101657198A (zh) * | 2007-04-12 | 2010-02-24 | Cv医药有限公司 | 增强胰岛素分泌的雷诺嗪 |
KR20100015685A (ko) | 2007-04-12 | 2010-02-12 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 인슐린 분비 강화를 위한 라놀라진 |
WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
WO2008144483A2 (en) * | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
WO2009026444A1 (en) | 2007-08-22 | 2009-02-26 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
KR20100054856A (ko) | 2007-09-12 | 2010-05-25 | 와이어쓰 엘엘씨 | 히스타민-3 길항제로서의 이소퀴놀리닐 및 이소인돌리닐 유도체 |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
KR20100101666A (ko) | 2007-12-19 | 2010-09-17 | 제넨테크, 인크. | 8-아닐리노이미다조피리딘 및 항암제 및/또는 소염제로서의 이들의 용도 |
PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
EP2231669A1 (en) | 2008-01-09 | 2010-09-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Phosphodiesterase inhibitors |
WO2009100380A1 (en) | 2008-02-06 | 2009-08-13 | Cv Therapeutics, Inc. | Use of ranolazine for treating pain |
CN101910169A (zh) | 2008-02-13 | 2010-12-08 | 卫材R&D管理有限公司 | 双环胺衍生物 |
JP2009286773A (ja) | 2008-03-14 | 2009-12-10 | Bayer Cropscience Ag | 殺虫性縮環式アリール類 |
US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
WO2009137499A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
DE102008024182A1 (de) | 2008-05-19 | 2009-11-26 | Merck Patent Gmbh | Verbindungen für organische elektronische Vorrichtung |
WO2009148452A1 (en) | 2008-06-06 | 2009-12-10 | Abbott Laboratories | Novel 1,2,4 oxadiazole compounds and methods of use thereof |
AU2009261764B2 (en) | 2008-06-17 | 2013-01-10 | Astrazeneca Ab | Pyridine compounds |
WO2010006292A1 (en) | 2008-07-11 | 2010-01-14 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
WO2010018686A1 (ja) | 2008-08-12 | 2010-02-18 | 日本曹達株式会社 | 含窒素ヘテロ環誘導体および農園芸用殺菌剤 |
CA2734449A1 (en) | 2008-08-18 | 2010-02-25 | Ube Industries, Ltd. | Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto |
EP2337559A2 (en) | 2008-09-04 | 2011-06-29 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
US20100113461A1 (en) | 2008-10-29 | 2010-05-06 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds |
US8389500B2 (en) * | 2008-10-30 | 2013-03-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
WO2010074807A1 (en) * | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
WO2010056865A1 (en) * | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Quinoline derivatives as ion channel modulators |
US20100130436A1 (en) * | 2008-11-25 | 2010-05-27 | Gilead Palo Alto, Inc. | Co-administration of ranolazine and cardiac glycosides |
WO2010077686A1 (en) | 2008-12-08 | 2010-07-08 | Sirtris Pharmaceuticals, Inc. | Isoindolinone and related analogs as sirtuin modulators |
US9040508B2 (en) | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
JP5271069B2 (ja) | 2008-12-24 | 2013-08-21 | 三和シヤッター工業株式会社 | 開閉装置 |
RS53941B1 (en) * | 2009-01-12 | 2015-08-31 | Pfizer Limited | SULFONAMID DERIVATIVES |
FR2943342B1 (fr) * | 2009-03-20 | 2011-03-04 | Servier Lab | Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
BRPI1012282A2 (pt) | 2009-03-27 | 2015-09-22 | Presidio Pharmaceuticals Inc | inibidores de anel fundidos da hepatite c. |
US20100305093A1 (en) * | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
CN102725290B (zh) | 2009-07-27 | 2016-03-09 | 吉利德科学股份有限公司 | 作为离子通道调节剂的稠合杂环化合物 |
NZ597833A (en) | 2009-09-28 | 2014-01-31 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
WO2011042920A1 (en) | 2009-10-07 | 2011-04-14 | Decode Genetics Ehf | Genetic variants indicative of vascular conditions |
WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
CN102791687B (zh) | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
PT2588197E (pt) | 2010-07-02 | 2015-02-09 | Gilead Sciences Inc | Compostos heterocíclicos fundidos como moduladores do canal de iões |
WO2012019076A1 (en) * | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
WO2012019071A1 (en) * | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
WO2012037105A1 (en) * | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
WO2012036233A1 (ja) | 2010-09-17 | 2012-03-22 | 塩野義製薬株式会社 | メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体 |
JP5977240B2 (ja) | 2010-09-21 | 2016-08-24 | パーデュー、ファーマ、リミテッド、パートナーシップ | ブプレノルフィン類似体 |
WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
EP2643316A2 (en) * | 2010-11-24 | 2013-10-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture |
JP5675428B2 (ja) | 2011-02-25 | 2015-02-25 | サンドビック株式会社 | ベルトプレス装置 |
EP2688891B1 (en) | 2011-03-21 | 2017-11-15 | F. Hoffmann-La Roche AG | Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
CN105693645B (zh) | 2011-05-10 | 2018-10-09 | 吉利德科学公司 | 作为离子通道调节剂的稠合杂环化合物 |
WO2012167212A2 (en) | 2011-06-03 | 2012-12-06 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
WO2013004551A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
NO3175985T3 (ru) | 2011-07-01 | 2018-04-28 | ||
US20140221286A1 (en) | 2011-09-21 | 2014-08-07 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
US8623860B2 (en) | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
WO2013112932A1 (en) | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
WO2013185764A2 (en) | 2012-06-13 | 2013-12-19 | Acesion Pharma | Pharmaceutical compositions for combination therapy |
WO2014134419A1 (en) | 2013-03-01 | 2014-09-04 | Gilead Sciences, Inc. | Use of ikach blockers for the treatment of cardiac diseases |
TW201613908A (en) | 2014-02-13 | 2016-04-16 | Gilead Sciences Inc | Solid forms of an ion channel modulator |
CN104844535A (zh) | 2014-02-13 | 2015-08-19 | 吉利德科学公司 | 用于制备稠合杂环离子通道调节剂的方法 |
-
2012
- 2012-06-28 TW TW101123291A patent/TWI478908B/zh not_active IP Right Cessation
- 2012-06-28 UY UY0001034171A patent/UY34171A/es not_active Application Discontinuation
- 2012-06-28 TW TW105120804A patent/TWI622583B/zh not_active IP Right Cessation
- 2012-06-28 TW TW107102252A patent/TW201837023A/zh unknown
- 2012-06-28 TW TW104100530A patent/TWI549944B/zh not_active IP Right Cessation
- 2012-06-29 CA CA2838223A patent/CA2838223A1/en not_active Abandoned
- 2012-06-29 NZ NZ618691A patent/NZ618691A/en not_active IP Right Cessation
- 2012-06-29 PE PE2013002817A patent/PE20140690A1/es active IP Right Grant
- 2012-06-29 EA EA201391639A patent/EA027356B1/ru not_active IP Right Cessation
- 2012-06-29 UA UAA201314145A patent/UA115529C2/uk unknown
- 2012-06-29 ES ES16169314T patent/ES2842433T3/es active Active
- 2012-06-29 HU HUE12735402A patent/HUE029398T2/en unknown
- 2012-06-29 AP AP2013007300A patent/AP2013007300A0/xx unknown
- 2012-06-29 US US13/538,847 patent/US8586732B2/en active Active
- 2012-06-29 WO PCT/US2012/045086 patent/WO2013006485A1/en active Application Filing
- 2012-06-29 AU AU2012279236A patent/AU2012279236B2/en not_active Ceased
- 2012-06-29 EP EP16169314.8A patent/EP3101013B1/en active Active
- 2012-06-29 PL PL12735402T patent/PL2726466T3/pl unknown
- 2012-06-29 EP EP16169386.6A patent/EP3085696B1/en active Active
- 2012-06-29 DK DK12735402.5T patent/DK2726466T3/en active
- 2012-06-29 EP EP16169333.8A patent/EP3088395B1/en active Active
- 2012-06-29 MD MDA20130095A patent/MD4371C1/ru not_active IP Right Cessation
- 2012-06-29 KR KR1020137033295A patent/KR101608927B1/ko active IP Right Grant
- 2012-06-29 CN CN201280042528.4A patent/CN103857659B/zh not_active Expired - Fee Related
- 2012-06-29 AR ARP120102370A patent/AR086828A1/es unknown
- 2012-06-29 BR BR112013032361A patent/BR112013032361A2/pt not_active Application Discontinuation
- 2012-06-29 SI SI201230579A patent/SI2726466T1/sl unknown
- 2012-06-29 CN CN201611165938.4A patent/CN106995415A/zh active Pending
- 2012-06-29 ES ES16169386T patent/ES2790633T3/es active Active
- 2012-06-29 EP EP16169320.5A patent/EP3098218B1/en active Active
- 2012-06-29 EA EA201790417A patent/EA201790417A3/ru unknown
- 2012-06-29 KR KR1020167008350A patent/KR20160040734A/ko not_active Application Discontinuation
- 2012-06-29 RS RS20160623A patent/RS55024B1/sr unknown
- 2012-06-29 EP EP16169306.4A patent/EP3085694B1/en active Active
- 2012-06-29 ES ES16169306T patent/ES2792864T3/es active Active
- 2012-06-29 PT PT127354025T patent/PT2726466T/pt unknown
- 2012-06-29 NZ NZ716245A patent/NZ716245A/en not_active IP Right Cessation
- 2012-06-29 ES ES16169320T patent/ES2797128T3/es active Active
- 2012-06-29 MX MX2013014846A patent/MX336810B/es active IP Right Grant
- 2012-06-29 JP JP2014519190A patent/JP5889407B2/ja not_active Expired - Fee Related
- 2012-06-29 ME MEP-2016-152A patent/ME02546B/me unknown
- 2012-06-29 ES ES12735402.5T patent/ES2583415T3/es active Active
- 2012-06-29 EP EP12735402.5A patent/EP2726466B1/en active Active
- 2012-06-29 ES ES16169333T patent/ES2792866T3/es active Active
-
2013
- 2013-03-07 US US13/789,469 patent/US8697863B2/en active Active
- 2013-09-26 US US14/038,646 patent/US9193694B2/en active Active
- 2013-11-29 ZA ZA2013/08981A patent/ZA201308981B/en unknown
- 2013-12-13 CR CR20130658A patent/CR20130658A/es unknown
- 2013-12-13 CO CO13291981A patent/CO6821960A2/es not_active Application Discontinuation
- 2013-12-16 CL CL2013003598A patent/CL2013003598A1/es unknown
- 2013-12-16 EC ECSP13013083 patent/ECSP13013083A/es unknown
- 2013-12-18 IL IL230022A patent/IL230022B/en active IP Right Grant
-
2014
- 2014-10-07 HK HK14109949.7A patent/HK1196602A1/zh unknown
-
2015
- 2015-10-01 US US14/872,787 patent/US9598435B2/en active Active
- 2015-12-28 JP JP2015255906A patent/JP6273250B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-11 US US15/152,231 patent/US9676760B2/en active Active
- 2016-07-27 HR HRP20160952TT patent/HRP20160952T1/hr unknown
- 2016-08-08 SM SM201600271T patent/SMT201600271B/it unknown
- 2016-08-18 CY CY20161100816T patent/CY1117915T1/el unknown
- 2016-12-08 HK HK16113998A patent/HK1225726A1/zh unknown
- 2016-12-08 HK HK16113997A patent/HK1225725A1/zh unknown
- 2016-12-08 HK HK16113995A patent/HK1225724A1/zh unknown
- 2016-12-15 HK HK16114299A patent/HK1226060A1/zh unknown
- 2016-12-15 HK HK16114300A patent/HK1226061A1/zh unknown
-
2018
- 2018-01-08 IL IL256779A patent/IL256779A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790417A3 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
EA201391532A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
EA201291272A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
EA201690899A1 (ru) | Оксазепины в качестве модуляторов ионных каналов | |
EA201290121A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
EA201690972A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
EA201391561A1 (ru) | Новые соединения-модуляторы gpr-119 | |
EA201301209A1 (ru) | Производные пирролотриазинона в качестве ингибиторов p13k | |
EA201591244A1 (ru) | Противовирусные соединения | |
EA201692166A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
EA201301019A1 (ru) | Бензодиоксановые ингибиторы продуцирования лейкотриена | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
WO2011056985A3 (en) | Substituted heterocyclic compounds | |
EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
EA201690521A1 (ru) | Способ получения замещенных 5-фтор-1h-пиразолопиридинов | |
EA201301181A1 (ru) | Триазолопиридины | |
EA201590562A1 (ru) | Бензамиды | |
WO2010056527A3 (en) | B-biphenyl sulfonamide compounds as ion channel modulators | |
EA201300389A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
EA201791321A1 (ru) | Составы ингибитора lfa-1 | |
EA201690988A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
UA109029C2 (en) | 2-HETARYL-2- (TETRAHIDRO-2-Furanylidene) acetonitrile and method for their preparation |